Post Q3 EVC Update
EVC's Q3 update cites $30 million for a single station, a broadcast-business sale and stronger positioning for 2027.
EVC's Q3 update cites $30 million for a single station, a broadcast-business sale and stronger positioning for 2027.
$NN https://t.co/zzA15wtgMZ
Got the $SITC dividend of $3 last night and used it to buy $ARI today which no longer trades as of 4pm today Sometimes you get to buy a luxury apartment tower in Downtown Brooklyn and get two hotels for free Managed to thread the needle Hope to get a hat trick in liquidations with $ELME $SITC and $ARI
You been long $PCT for some time. And communicating with he of the Pink Dildo Fund. I mean Mike must be very smart. He think that Dan Gibson is a genius - and that is his refutation of my PCT short. (My thesis is simple: Dan Gibson is an idiot. My thesis does not involve Mike Taylor.) https://t.co/kDkDVkfDSl
@Mike_Taylor1972 @LevelUp975 Yes Sir. $PCT is the flagship stock in your Pink Dildo Fund. 🍆
2 nice blowups of two of my largest shorts today. $NRDS down 30% and $BL down 20%. Closing half of my $BL as it's no longer silly, and it's a decent business. Am considering adding to $NRDS as this result confirms the bear thesis that they are having to pay more for traffic.
Transocean’s 25.6% selloff reflects oil-market shorting and weak Q3 headlines, while debt reduction after the Valaris acquisition could…
Alpha Metallurgical posted a third consecutive quarterly loss as High Vol A coal margins fell to $14 a ton, while director Kenneth Courtis…
Shift4’s Q3 met guidance, but organic growth is decelerating, management credibility is weakening and leverage reduction remains too slow.
Diversified Energy reported $255.6 million of “true” nine-month free cash flow, while its $1.8 billion Birch acquisition would shift…
Vicor earns a Strong Buy after record Q3 results and AI gains, while QXO falls to Hold over capital structure and execution risk.
TransMedics reported record Q3 2026 revenue exceeding $200 million, driven by its organ transplant technology business.
JFrog jumped 35% to $100.44 after another beat-and-raise quarter, joining the TL20 Special Situations group.
Twist Bioscience’s $200 rebound followed an Anthropic-linked short squeeze, yet its DNA and protein services face broad competition while…
Vishay reported record Q3 revenue of $979 million, up 24%, and guided Q4 to about $990 million as rising backlog and margins contrast with…
ELALF · long El Al Israel Airlines, $ELAL, cut costs 20% in its 2020 COVID restructuring and was taken over by U.S. investors.
Eton Pharmaceuticals licensed rare-disease medicines, raised revenue guidance twice and climbed more than fourfold from its February 2026…
TG Therapeutics' Briumvi growth and subcutaneous formulation progress have fueled takeover rumors, with Biogen, Incyte and Sanofi cited as…
Churchill Downs is selling regional casinos to focus on horse racing and historical racing machines, where Exacta software and racetrack…
Re/Max’s outstanding share count is revised after previously omitted shares under its holding-company structure, alongside updated Real…
Modine's leaked database identifies Google behind a $4 billion agreement and $4.5 billion of additional demand, with nearly $15 billion of…
IRhythm’s ZEUS clearance cuts clinician review time 50%, targeting $100 million in five-year savings as cardiac monitoring margins expand…
Real Brokerage’s RE/MAX acquisition would triple its agent count, diversify revenue with franchise fees and expand share during a weak U.S.
Corcept Therapeutics expects Lifyorli and Korlym to support 44% revenue growth, while FDA and European decisions on relacorilant could…
El Al trades near 2x EBITDA after wartime near-monopoly profits, with $1.3 billion of net cash and owned aircraft weighed against…
Every publication on this site, hand-picked.
Every account on this site, hand-picked.
Ordered by how often our editor reaches for them.